27 November 2018

NICE, Level 1, City Tower, Piccadilly Plaza, Manchester, M1 4BT

Final Agenda 

The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00

Please note that this agenda is subject to change before the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Code of conduct for members of the public attending the meeting – Part 1 only (open session)
  3. Apologies – Part 1 only (open session)
  4. Any other business – Part 1 only (open session)
  5. Appraisal of pacritinib for treating myelofibrosis [ID880]
    The Committee for Medicinal Products for Human Use (at the European Medicines Agency) has not yet given its regulatory opinion for pacritinib for treating
    myelofibrosis and as a consequence this discussion will take place in a Part 2 session. (Part 2 sessions are closed to public observers).
    • 5.1. Declarations of interest – Part 2 only (closed session)
    • 5.2. Introduction by the Vice-Chair, Dr Peter Selby  Part 2 only (closed session)
    • 5.3. Presentation by the lead team: Rubin Minhas, Andrea Manca and David Chander– Part 2 only (closed session)
    • 5.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  6. Appraisal of brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma [ID1190]
    • 6.1. Declarations of interest – Part 1 only (open session)
    • 6.2. Introduction by the Vice-Chair, Dr Peter Selby – Part 1 only (open session)
    • 6.3. Presentation by the lead team: Richard Nicholas, Matt Stevenson and Judith Wardle  Part 1 AND part 2 (open and closed session)
    • 6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of venetoclax with rituximab for treating relapsed or refractory chronic lymphocytic leukaemia [ID1097]
    • 7.1. Declarations of interest – Part 1 only (open session)
    • 7.2. Introduction by the Chair, Professor Stephen O’Brien  Part 1 only (open session)
    • 7.3. Presentation by the Chair, Professor Stephen O’Brien  Part 1 AND part 2 (open and closed session)
    • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on Thursday 3 January 2019 at 10:00am, NICE, Level 1, City Tower, Piccadilly Plaza, Manchester, M1 4BT

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on Tuesday 13 November 2018Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Sandra Robinson.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 30 October 2018 to 13 November 2018
Registration is closed.